Company is commercial stage bioscience company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Company recently closed $30 million Series B funding with several high-level investment partners.
Company has game changing technology in the neurology space. Technology is industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity.
Ground floor level with well invested start-up
Company equity/stock
Start-up culture and entrepreneur mindset
Game changing technology
$130k plus base salary, $230k plus total comp
